Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease

BMC Infectious Diseases
Tsukasa KadotaKen Ohta

Abstract

Although the isolation of clarithromycin (CAM)-resistant Mycobacterium avium complex (MAC) indicates a poor treatment outcome and increased mortality, there have been only a few reports on drug treatment for CAM-resistant MAC lung disease. We aimed to reveal the effectiveness of the continuation of a macrolide and the use of a multidrug regimen in the treatment of CAM-resistant MAC lung disease. Among patients with MAC pulmonary disease as defined by the 2007 criteria of the American Thoracic Society and the Infectious Diseases Society of America statement, those with CAM-resistant MAC (minimum inhibitory concentration ≥32 μg/ml) isolated, newly diagnosed and treated from January 2009 to June 2013 were analysed in this study. Effectiveness was measured based on culture conversion rate and improvement of radiological findings. Thirty-three HIV-negative patients were analysed in this study. Twenty-six were treated with a regimen containing CAM or azithromycin (AZM), and 21 patients were treated with three or more drugs except macrolide. The median duration to be evaluated was 10.4 months after beginning the treatment regimen. Sputum conversion (including cases of inability to expectorate sputum) was achieved in 12 (36%) patients....Continue Reading

References

May 1, 1994·American Journal of Respiratory and Critical Care Medicine·R J WallaceG H Mazurek
Jun 1, 1996·American Journal of Respiratory and Critical Care Medicine·R J WallaceD T Murphy
Apr 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C M Kunin
Jun 25, 1998·American Journal of Respiratory and Critical Care Medicine·S KudohM Ando
Sep 3, 1999·American Journal of Respiratory and Critical Care Medicine·E TanakaF Kuze
Jul 22, 2006·American Journal of Respiratory and Critical Care Medicine·David E GriffithRichard J Wallace
Feb 6, 2007·American Journal of Respiratory and Critical Care Medicine·David E GriffithUNKNOWN Infectious Disease Society of America
May 24, 2008·The Annals of Thoracic Surgery·John D MitchellMarvin Pomerantz
Aug 30, 2008·American Journal of Respiratory and Critical Care Medicine·Terence A R SeemungalJadwiga A Wedzicha
Aug 8, 2009·American Journal of Respiratory and Critical Care Medicine·Kyeongman JeonWon-Jung Koh
May 29, 2010·American Journal of Respiratory and Critical Care Medicine·Kevin L WinthropKatrina Hedberg
Jun 12, 2010·American Journal of Respiratory and Critical Care Medicine·D Rebecca PrevotsKenneth N Olivier
Aug 26, 2011·The New England Journal of Medicine·Richard K AlbertUNKNOWN COPD Clinical Research Network
Sep 20, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Masaki FujitaYoichi Nakanishi
Dec 30, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshihiro KobashiMikio Oka
Feb 14, 2012·Current Opinion in Infectious Diseases·David E Griffith, Timothy R Aksamit
Jun 30, 2012·American Journal of Respiratory and Critical Care Medicine·Jakko van IngenCharles L Daley
Mar 13, 2013·Antimicrobial Agents and Chemotherapy·Won-Jung KohSung Jae Shin
Apr 27, 2013·The Annals of Thoracic Surgery·Yuji ShiraishiKiyomi Shimoda

❮ Previous
Next ❯

Citations

Jun 8, 2018·American Journal of Respiratory and Critical Care Medicine·Byung Woo JhunWon-Jung Koh
May 22, 2019·Open Forum Infectious Diseases·Takanori AsakuraNaoki Hasegawa
Jul 2, 2019·Expert Review of Respiratory Medicine·Yong-Soo KwonWon-Jung Koh
Dec 24, 2018·Tuberculosis and Respiratory Diseases·Yong Soo KwonCharles L Daley
Oct 13, 2019·Respiratory Medicine·Kozo MorimotoSatoshi Mitarai

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
X-ray

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cavernous Hemangioma

Cavernous hemangioma is a blood vessel defect or benign tumor that leads to leakage of blood to the surrounding tissues. This can occur in several organs including the brain, which can lead to seizures. Discover the latest research on cavernous hemangiomas here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.